Verification of the Ventana Anti-ALK (D5F3) Antibody in the Detection of EML4-ALK Rearrangement in Non-Small Cell Lung Cancer

被引：0
|
作者：
Narine, Nadira
Rana, Durgesh
机构：
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2015年 / 144卷
关键词：
D O I：
10.1093/ajcp/144.suppl2.086
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
086
引用
收藏
页码：A86 / A86
页数：1
相关论文
共 50 条
  • [21] EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Zhijie
    Zhang, Xuchao
    Bai, Hua
    Zhao, Jun
    Zhuo, Minglei
    An, Tongtong
    Duan, Jianchun
    Yang, Lu
    Wu, Meina
    Wang, Shuhang
    Wang, Yuyan
    Wu, Yilong
    Wang, Jie
    ONCOLOGY, 2012, 83 (05) : 248 - 256
  • [22] ANALYSIS OF EML4-ALK POSITIVE NON-SMALL CELL LUNG CANCER WITH ADVANCED STAGE
    Park, J.
    Kondo, C.
    Shimizu, J.
    Horio, Y.
    Yoshida, K.
    Yatabe, Y.
    Mitsudomi, T.
    Hida, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 433 - 434
  • [23] EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer Response
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (05) : 578 - 578
  • [24] ALK Immunohistochemical Staining with Anti-ALK Antibody (Clone D5F3) Is a Reliable Method to Detect ALK Rearrangement in Lung Adenocarcinomas: A Study of Consecutive 879 Cases in The Chinese Population
    Sun, Y.
    Zhou, L.
    Huang, X.
    Kang, Q.
    Jia, L.
    Li, X.
    Cao, D.
    MODERN PATHOLOGY, 2014, 27 : 496A - 496A
  • [25] RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report
    Yan, Huan
    Zeng, Liang
    Zhang, Yongchang
    HELIYON, 2024, 10 (09)
  • [26] Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas
    Conde, Esther
    Hernandez, Susana
    Prieto, Mario
    Martinez, Rebeca
    Lopez-Rios, Fernando
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (06) : 707 - 713
  • [27] EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
    Huang, Thomas
    Engelmann, Brigitte J.
    Morgan, Rachael M.
    Absher, Kimberly J.
    Kolesar, Jill M.
    Villano, John L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 965 - 968
  • [28] EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas
    Shinmura, Kazuya
    Kageyama, Shinji
    Igarashi, Hisaki
    Kamo, Takaharu
    Mochizuki, Takahiro
    Suzuki, Kazuya
    Tanahashi, Masayuki
    Niwa, Hiroshi
    Ogawa, Hiroshi
    Sugimura, Haruhiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (02) : 271 - 275
  • [29] EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
    Erik Thunnissen
    Lukas Bubendorf
    Manfred Dietel
    Göran Elmberger
    Keith Kerr
    Fernando Lopez-Rios
    Holger Moch
    Wlodzimierz Olszewski
    Patrick Pauwels
    Frédérique Penault-Llorca
    Giulio Rossi
    Virchows Archiv, 2012, 461 : 245 - 257
  • [30] EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
    Gower, Arjan
    Hsu, Wei-Hsun
    Hsu, Shuo-Tse
    Wang, Yisong
    Giaccone, Giuseppe
    MOLECULAR ONCOLOGY, 2016, 10 (04) : 601 - 609
12345